4-Aminopyridine, Atenolol, or Placebo in Patients With Vestibular Migraine

Withdrawn before enrolling · Phase 2 · Has a placebo group

Conditions studied: Vestibular Migraine, Migraine Disorders, Vestibular Diseases

In brief

This phase 2 randomized study will be used to test the efficacy of 4-aminopyridine (4AP) or atenolol to reduce severity and frequency of vestibular and headache symptoms of vestibular migriane sufferers. Blinded study drug will be taken by mouth twice a day for 14 weeks on study.

Key facts

Study ID

NCT03578354

Run by

Massachusetts Eye and Ear Infirmary

People needed

0

Starts

2019-01-01

Expected to finish

2024-08-01

Last updated by the study team

2024-07-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Severe vestibular migraine (VM)

You may not qualify if…

• Neurologic or otologic disease other than VM
• Psychiatric illness requiring medication
• Medical illness including cancer, coronary artery or cerebrovascular disease
• Known allergy to one of the test medications
• Contraindication to use of one of the test medications - asthma, symptomatic hypotension, history of seizures
• Taking migraine prophylactic medication or vestibular suppressants.
• Pregnant or breast feeding women

Where it is running

• Massachusetts Eye and Ear Infirmary — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.